Trial reportEuropean journal of haematology2019
Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients.
Trial report in European journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials.Cancers · 2023Guideline
- Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1.Blood neoplasia · 2026Trial
- Trial
- Mixed-Methods to Define Meaningful Change using Exit Interviewand Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT).Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Trial
- Trial
- Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group.Journal of patient-reported outcomes · 2024Trial
- Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients.European journal of haematology · 2019Trial
- Improving quality of life in older dialysis patients: the case for broader functional assessment.Clinical kidney journal · 2026Article
- Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).Blood cancer journal · 2024Article
- A multidisciplinary group-based survivorship intervention for those living with multiple myeloma: a feasibility study.Pilot and feasibility studies · 2024Article
- In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.Blood cancer journal · 2023Article
- Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.Journal of the advanced practitioner in oncology · 2023Article
- Physical and mental health of breast cancer patients and survivors before and during successive SARS-CoV-2-infection waves.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development.Blood cancer journal · 2023Review
- Comparison of anchor-based methods for estimating thresholds of meaningful within-patient change using simulated PROMIS PF 20a data under various joint distribution characteristic conditions.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- An explanatory sequential mixed-methods design to establish thresholds of within-individual meaningful change on a sleep disturbance numerical rating scale score in atopic dermatitis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Article
- Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.Blood advances · 2022Article
- Triangulation of multiple meaningful change thresholds for patient-reported outcome scores.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesThresholds for the minimally important difference (MID) or responder definition (RD) in health-related quality-of-life (HRQoL) scores are required to interpret the impact of an intervention or change in the trajectory of the condition which is meaningful to patients. This study aimed to establish MID and RD for the European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma questionnaire (EORTC QLQ-MY20).
methodsA novel mixed-methods approach was applied by utilizing both existing clinical trial data and prospective patient interviews. Anchor-based, distribution-based, and qualitative-based estimates of meaningful change were triangulated to form recommended RDs for each scale of the EORTC QLQ-MY20. Anchor-based MIDs were summarized using weighted correlation.
resultsRecommended MIDs were as follows: Disease Symptoms (DS 10 points), Side Effects of Treatment (SE 10 points), Body Image (BI 13 points), and Future Perspective (FP 9 points). Recommended RDs were as follows: DS (16 improvement; 11 worsening), SE (6 improvement; 9 worsening), BI (33 improvement; 33 worsening), and FP (11 improvement; 11 worsening).
conclusionsThe study generated estimates of the MID and RD for each scale of the EORTC QLQ-MY20. Published estimates will enable investigators and clinicians to adopt these as standard for interpretation and for hypothesis testing. Consequently, analyses from trials of different interventions can be more comparable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.